Navigation Links
Michael J. Fox Foundation Commits up to $3.8 Million to Develop Gene Silencing Neuroprotective Treatment for Parkinson's Disease
Date:1/4/2008

NEW YORK, Jan. 4 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation has committed up to $3.8 million for the development of a gene silencing therapeutic to treat Parkinson's disease by reducing expression of the protein alpha-synuclein. A team of researchers led by Matt Farrer, PhD, of Mayo Clinic Jacksonville (Florida) with collaborators at Alnylam Pharmaceuticals and The Parkinson's Institute and Clinical Center will work to optimize a small interfering RNA (siRNA)-based therapeutic that could slow or stop the progression of Parkinson's disease. If successful, the project could result in an entirely new class of drug targeting the alpha-synuclein gene, which has proved difficult to modulate using traditional small-molecule therapeutics.

The work is being funded under the Foundation's LEAPS (Linked Efforts to Accelerate Parkinson's Solutions) 2007 initiative. LEAPS 2007 was funded with a lead gift from the Edmond J. Safra Philanthropic Foundation. The Edmond J. Safra Philanthropic Foundation has been one of the most steadfast supporters of The Michael J. Fox Foundation since its inception.

"Available Parkinson's treatments mask symptoms but do nothing to halt or slow underlying disease progression," said Katie Hood, chief executive officer of MJFF. "More and more scientific evidence supports the hypothesis that lowering alpha-synuclein levels in the brain could achieve the so-called 'Holy Grail' of PD research, a neuroprotective therapy. But no drugs have been identified to date that are capable of reducing alpha-synuclein expression; new approaches are needed. This LEAPS grant is characteristic of how The Michael J. Fox Foundation goes about its work -- making big bets on fresh ideas with potential to impact patients' quality of life."

While its normal function in the brain remains unknown, the accumulation of excess alpha-synuclein has been shown to be the cause of some familial forms of PD. Clinical, genetic and experimental evidence exists to show that alpha-synuclein accumulation in neurons may be a key feature of non-inherited PD as well. Continued research will analyze whether reducing the levels of alpha-synuclein in the brains of people with Parkinson's can slow the progression of the disease.

RNA interference (RNAi) is a natural mechanism present in all cells whereby small RNA molecules (the siRNAs) specifically silence gene expression by the targeted destruction of messenger RNA, the molecule that contains the instructions for protein synthesis.

In previous work funded under The Michael J. Fox Foundation's Target Validation initiative, the LEAPS researchers have demonstrated that targeted siRNAs reduce alpha-synuclein levels in mouse models of Parkinson's disease. They will now push this work forward by identifying the optimal alpha-synuclein siRNA drug candidate, then establishing efficacy and the "therapeutic window" for brain infusion in animal models. If successful, this project could ultimately lead to the development of an alpha-synuclein siRNA candidate drug that, in the future, could be tested in PD patients in Phase I clinical trials.

LEAPS awards, the signature funding initiative of The Michael J. Fox Foundation, are multi-year, multi-million, multi-disciplinary projects addressing questions with significant practical impact on the treatment of Parkinson's disease. Continued funding is dependent on completion of predetermined milestones at specific stages.

In addition to coordinating principal investigator Dr. Farrer, professor of neurogenetics, Department of Neuroscience, Mayo Clinic Jacksonville, this LEAPS team includes:

Jada Lewis, PhD, Assistant Professor, Department of Neuroscience, Mayo Clinic Jacksonville -- Dr. Lewis will hold primary responsibility for optimizing siRNAs in various mouse models of Parkinson's disease.

Donato A. DiMonte, MD, Professor, Director of Basic Research, The Parkinson's Institute and Clinical Center, Sunnyvale, California -- Dr. DiMonte, an expert in primate neurology, will hold ultimate responsibility for demonstrating that the candidate siRNAs are neuroprotective in primate models of PD.

David A. Bumcrot, PhD, Director, Research, Alnylam Pharmaceuticals, Cambridge, Massachusetts -- Dr. Bumcrot will spearhead the design and synthesis of all candidate siRNAs and lead efforts on investigating siRNA delivery strategies.

While many LEAPS projects involve commercial entities, funds are for stated projects only, dependent upon completion of predetermined milestones at specific stages, and do not represent equity investments. If all milestones are met, this LEAPS allocation will be as follows (rounded figures):

-- Mayo Clinic: $1.9 million

-- The Parkinson's Institute: $1.4 million

-- Alnylam: $546,000

About The Michael J. Fox Foundation

Founded in 2000, The Michael J. Fox Foundation for Parkinson's Research is dedicated to ensuring the development of a cure for Parkinson's disease within this decade through an aggressively funded research agenda. The Foundation has funded approximately $110 million in research to date.


'/>"/>
SOURCE Michael J. Fox Foundation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Michael Moores SiCKO Becomes the Third Highest Grossing Documentary of All Time Surpassing An Inconvenient Truth
2. Katie Hood Appointed Interim Chief Executive Officer of Michael J. Fox Foundation
3. Clarient Names Michael J. Pellini, M.D. Chief Operating Officer
4. Digital Healthcare Announces Dr. Michael Fleming Joins Executive Team as Medical Director
5. Michael J. Fox Foundation Commits Up to $2 Million for PD Drug Development Under Target Validation 2008
6. BioElectronics Corporation Announces Addition of Michael Seidenman, R.Ph. as Vice President of Sales
7. BioSeek Appoints Michael C. Venuti, Ph.D., Chief Executive Officer
8. Irene Hegeman Richard, MD, Appointed Senior Medical Advisor to The Michael J. Fox Foundation
9. Actress Jenifer Lewis, Authors Dr. Michael Eric Dyson and Susan Taylor Among Featured Speakers for Senator Hughes Behavioral Mental Health Summit
10. Michael J. Fox Foundation Launches Rapid Response Innovation Awards 2008 Following Strong Inaugural Year Response
11. Siemens Medical Solutions Michael Long Recognized as one of Computerworlds 2008 Premier 100 IT Leaders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Cary, North Carolina (PRWEB) , ... June 26, 2016 , ... ... the release of a new product that was developed to enhance the health of ... harvested for centuries. , The two main herbs in the PawPaws Cat Kidney ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016  In a startling report released today, National Safety ... lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... how states are tackling the worst drug crisis in recorded U.S. ... Kentucky , New Mexico , ... Of the 28 failing states, three – Michigan ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
(Date:6/23/2016)... Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new ... affiliate in Latin America . ... ... ... ...
Breaking Medicine Technology: